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Abstract Hepatocellular carcinoma (HCC) is the second cause of cancer-related death in the world and is
 the main cause of death in cirrhotic patients. Unfortunately, the incidence of HCC has grown sig-
nificantly in the last decade. Curative treatments such as surgery, liver transplantation or percutaneous ablation 
can only be applied in less than 30% of cases. The multikinase inhibitor sorafenib is the first line therapy for 
advanced HCC. Regorafenib is the standard of care for second-line patients. However, novel and more specific 
potent therapeutic approaches for advanced HCC are still needed. The liver constitutes a unique immunological 
microenvironment, although anti-tumor immunity seems to be feasible with the use of checkpoint inhibitors such 
as nivolumab. Efficacy may be further increased by combining checkpoint inhibitors or by applying loco-regional 
treatments. The success of immune checkpoint blockade has renewed interest in immunotherapy in HCC.
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Resumen Anticuerpos monoclonales inmunoestimulantes para el tratamiento del hepatocarcinoma.
 Avances y perspectivas. El hepatocarcinoma (HCC) es la segunda causa de muerte relacionada 
con el cáncer en el mundo y es la principal causa de muerte en pacientes cirróticos. Desafortunadamente, la 
incidencia de HCC ha crecido significativamente en la última década. Los tratamientos curativos como la cirugía, 
el trasplante de hígado o la ablación solo pueden aplicarse en menos del 30% de los casos. El sorafenib es el 
tratamiento de primera línea para el HCC avanzado, mientras que el regorafenib se reserva como segunda línea. 
Sin embargo, todavía son necesarios nuevos enfoques terapéuticos potentes y más específicos para el HCC 
avanzado. El hígado constituye un microambiente inmunológico único, aunque la inmunidad antitumoral parece 
ser factible mediante el uso de inhibidores de punto de control como nivolumab. La eficacia puede aumentarse 
adicionalmente combinando inhibidores de puntos de control inmunitario o aplicando tratamientos loco-regionales. 
En este sentido, el éxito del uso de anticuerpos monoclonales, que bloquean el control inmunitario, ha renovado 
el interés en la inmunoterapia para el HCC.
 Palabras clave: hepatocarcinoma, anticuerpos inmunoestimuladores, antígeno-4 asociado al linfocito T citotóxico 
(CTLA-4), ligando de la molécula de muerte celular programada 1 (PD1-L), linfocitos infiltrantes 
tumorales 
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Hepatocellular carcinoma (HCC) is the second cause 
of cancer-related death worldwide and its incidence is 
steadily increasing1. HCC primarily develops from cirrho-
sis, and most patients are infected with hepatitis C or B 
virus2. Non-viral HCC etiologies, such as diabetes mellitus 
and non-alcoholic steatohepatitis (NASH), are growing 
in frequency particularly in Western European patients3. 
Unfortunately, more than 750 000 cases are diagnosed 
each year and the majority of them are at advanced stages 
when curative treatments are very difficult to apply1, 4. For 
advanced HCC, the first line systemic therapy option is the 
multikinase inhibitor sorafenib, which offers an increase 
in overall survival from 7.9 months to 10.7 months when 
compared to placebo5. Although a large majority of pa-
tients progress on sorafenib, treatment with regorafenib 
in second line, a similar molecule in terms of mechanisms 
of antitumoral activity and side effects, improved overall 
survival by 2.8 months vs. placebo6. Therefore, there is 
an urgent need for more effective options for patients with 
advanced HCC.  
Liver immunotolerance
It is well known that cancer is a complex and multifactorial 
disease; tumor cells have the ability to release a number 
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of factors that can assist their capacity to grow and me-
tastasize7. One of the most important characteristics of 
tumors is their capacity to evade immune surveillance8, 9. 
Preclinical and clinical data demonstrated that the intra-
tumoral microenvironment is highly immunosuppressive 
and there is a poor effector T cell response in advanced 
HCC10. Independently of the causative disease, HCC 
can be considered as an inflammatory tumor composed 
by different types of immune cells that tilt the balance 
toward a state of immunotolerance8. This immunosup-
pressive microenvironment is characterized, at least in 
part, by the presence of CD4+ FoxP3+ T cells (Tregs), 
type 2 macrophages, myeloid-derived suppressor cells, 
tumor associated fibroblasts, Kupffer cells, just to men-
tion a few11. It has been previously reported that tumor-
infiltrating lymphocytes correlate with improved survival 
in patients with HCC12. Thus, it is reasonable to consider 
immunotherapy as a rational therapeutic tool for patients 
with advanced or progressed HCC. The main goal of the 
majority of immunotherapy approaches is to generate a 
potent specific cytotoxic T cell response against cancer 
cells. The list of strategies applied so far include tumor 
vaccines, adoptive T cell therapy (including CAR-T cells), 
immune-gene therapy with oncolytic vectors, dendritic 
cells-based vaccines and, more recently, the use of im-
munostimulatory monoclonal antibodies, particularly the 
immune checkpoint inhibitors13. Checkpoint blockade 
has become a major focus in the immune-based therapy 
of HCC. The main concept involves inhibition of regula-
tory cell surface molecules, which normally inhibit T-cell 
activation.
Immune checkpoint antibody therapy for HCC 
Sangro et al14 demonstrated in a pilot study that the 
Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) inhibitor 
tremelimumab has promising antitumoral activity in pa-
tients with advanced HCC with hepatitis C virus infection. 
Twenty patients were treated with tremelimumab resulting 
in 17.6% of partial response and an overall survival of 8.2 
months. More recently, a phase 1/2 dose escalation and 
expansion trial (CheckMate 040) evaluated nivolumab in 
sorafenib-naïve as well as in sorafenib-experienced HCC. 
Nivolumab is a fully human (IgG4) monoclonal antibody 
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TABLE 1.– Clinical trials using immunostimulatory monoclonal antibodies for advanced hepatocellular carcinoma
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inhibitor of the programmed death-1 (PD-1) receptor that 
restores T-cell–mediated antitumor activity15. Nivolumab 
has demonstrated clinical benefit in melanoma, refractory 
non-small cell lung cancer, advanced renal cell carcinoma, 
Hodgkin lymphoma, squamous cell carcinoma of the head 
and neck, and urothelial carcinoma16. In the CheckMate 
040 study, 262 patients were enrolled and the primary 
end point was safety and tolerability (escalation phase) 
and overall response rate (expansion phase). As a result, 
in sorafenib-experienced patients with or without chronic 
viral hepatitis, nivolumab demonstrated a long-term sur-
vival and durable objective responses; in addition, safety 
profiles of nivolumab were similar to what has been ob-
served in other tumor types; importantly, hepatic safety 
events were also manageable. Of note, clinical responses 
occurred irrespective of PD-L1 expression on cancer 
cells. A phase 3 study evaluating nivolumab in systemic 
treatment–naïve patients with advanced HCC is being 
carried out (CheckMate 459, ClinicalTrials.gov identifier 
NCT02576509) and will be of paramount importance if 
the study confirms the results obtained with nivolumab 
in phase 1/2 trial.
These promising results open the possibility for combi-
nations using checkpoint inhibitors such as tremelimumab 
with other strategies, for example loco-regional treatments 
(local ablation or trans-arterial chemoembolization) which 
release tumor antigens into the bloodstream. Duffy et al 
reported promising results in terms of overall survival 
and objective responses; interestingly, patients showing 
increased intratumoral levels of CD8+ T cells, reached 
better clinical outcome17.  
Nivolumab showed similar immune-related adverse 
events in HCC patients in comparison with other types 
of tumors; no serious liver dysfunction or autoimmune 
disease was observed17. El-Khoueiry et al reported that 
in the dose-escalation phase of the CheckMate040 trial 
only one of 48 patients who received nivolumab at the 
dose of 3 mg/kg discontinued therapy due to elevated 
liver transaminases. One patient showed grade 4 toxicity 
because of increased lipase, and the only grade 3 events 
were elevated AST levels in 5 patients and elevated ALT 
levels in 4 more patients15. In the dose expansion phase 
(n = 214) HCC patients were treated with 3 mg/kg; in this 
phase, 40 (19%) patients presented grade 3/4 treatment-
related adverse events15 (Table 1).
Recently, Rammohan et al reported the first case 
of metastatic HCC following liver transplantation that 
responded to the PD-1 inhibitor pembrolizumab, after 
the failure of sorafenib therapy18. The patient showed 
complete radiological response and remains well with no 
evidence of tumor recurrence or organ rejection19.
In conclusion, the liver constitutes a unique immuno-
logical microenvironment, with multiple immunotolerant 
mechanisms that favor HCC development. Re-estab-
lishing anti-tumor immunity seems to be feasible and the 
results with checkpoint inhibitors such as nivolumab 
are promising; however, confirmation of the efficacy of 
nivolumab in the phase 3 clinical trial is pending. It is also 
important to identify predictive immunological biomarkers 
to help hepatologists in therapeutic decision-making. Ef-
ficacy may be further increased by combining checkpoint 
inhibitors (e.g. nivolumab and ipilimumab), though with in-
creased toxicity, or by applying loco-regional treatments. 
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